Hungarian pharma grabs rivals for $1.5B

While all eyes were on other potential mergers, Hungary's Richter Gedeon made two deals that will boost it to the top of Central and Eastern Europe's pharma industry.

In a $1.32 billion buyout, Richter will acquire Poland's Polpharma, which went private in 2000 and has been growing ever since. At the same time, Richter will fork over $126.4 million for an 80 percent stake in Russia's OAO Akrihin. The deals will be done via stock swap with Genefar, which owns Polpharma and a stake in OAO Akrihin (the latter as part of an investor group). Thus Richter will grow to a market cap of $5.3 billion, and Genefar will end up with a stake of 26.75 percent.

The deals appear to be Richter's way of growing out of a slump. Because of budget-cutting in Hungary, Richter has seen domestic sales drop; in the third quarter, those revenues fell 24 percent. Post-buyouts, the company expects a quarter of its sales to come from Poland and another 20 percent from Russia, with only 20 percent sourced at home.

- check out this release on the buyout
- read the report from the Budapest Business Journal
- get more details from Monsters and Critics

Related Articles:
Tips for a successful biotech sector. Report
Who's next on the biotech buyout hit list? Report
Should Pharma take the M&A cure? Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.